Integral Molecular touts Pa. grant to advance COVID-19 research

By The Science Advisory Board staff writers

September 21, 2020 -- Integral Molecular was awarded over $520,000 from the state of Pennsylvania to leverage its technologies in COVID-19 research. The grant will enable the company and its partners to develop therapies and vaccines against SARS-CoV-2.

Four of Integral Molecular's technology platforms are being used in the fight against the virus, including:

  • MPS Antibody Discovery platform to generate reactive antibodies against SARS-CoV-2 and other coronaviruses
  • SARS-CoV-2 reporter virus particles (RVPs) to test the safety for neutralizing immune responses in patients and vaccines
  • Membrane protein array (MPA) to rapidly screen for specificity of antibodies for SARS-CoV-2
  • Shotgun mutagenesis epitope mapping to optimize vaccine and antibody design

The funding was received through the state's COVID-19 Vaccines, Treatments, and Therapies (CV-VTT) program.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?